CA994753A - Solvates of antiinflammatory steroids and their use in aerosol formulations - Google Patents

Solvates of antiinflammatory steroids and their use in aerosol formulations

Info

Publication number
CA994753A
CA994753A CA169,205A CA169205A CA994753A CA 994753 A CA994753 A CA 994753A CA 169205 A CA169205 A CA 169205A CA 994753 A CA994753 A CA 994753A
Authority
CA
Canada
Prior art keywords
solvates
aerosol formulations
antiinflammatory steroids
antiinflammatory
steroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA169,205A
Other languages
English (en)
Other versions
CA169205S (en
Inventor
Peter B. Cook
John H. Hunt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allen and Hanburys Ltd
Original Assignee
Allen and Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10112152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA994753(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allen and Hanburys Ltd filed Critical Allen and Hanburys Ltd
Application granted granted Critical
Publication of CA994753A publication Critical patent/CA994753A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA169,205A 1972-04-20 1973-04-19 Solvates of antiinflammatory steroids and their use in aerosol formulations Expired CA994753A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1842172A GB1429184A (en) 1972-04-20 1972-04-20 Physically anti-inflammatory steroids for use in aerosols

Publications (1)

Publication Number Publication Date
CA994753A true CA994753A (en) 1976-08-10

Family

ID=10112152

Family Applications (1)

Application Number Title Priority Date Filing Date
CA169,205A Expired CA994753A (en) 1972-04-20 1973-04-19 Solvates of antiinflammatory steroids and their use in aerosol formulations

Country Status (23)

Country Link
US (2) US4414209A (es)
JP (1) JPS531814B2 (es)
AR (1) AR196524A1 (es)
AT (1) AT348115B (es)
AU (1) AU471577B2 (es)
BE (1) BE798458A (es)
CA (1) CA994753A (es)
DE (1) DE2320111C2 (es)
DK (1) DK134923B (es)
ES (1) ES413911A1 (es)
FI (1) FI53067C (es)
FR (1) FR2182981B1 (es)
GB (1) GB1429184A (es)
HU (1) HU171209B (es)
IE (1) IE37541B1 (es)
IL (1) IL42038A (es)
LU (1) LU67462A1 (es)
NL (1) NL157797B (es)
NO (1) NO140303C (es)
PH (1) PH13620A (es)
SE (1) SE399642B (es)
YU (1) YU39602B (es)
ZA (1) ZA732713B (es)

Families Citing this family (290)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933168A (en) * 1975-05-27 1990-06-12 Syntex Pharmaceuticals International Limited Stable, crystalline flunisolide
MX3864E (es) * 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
IT1121513B (it) * 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
ATE3774T1 (de) * 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5562608A (en) * 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
WO1993011744A1 (en) 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
ES2177544T3 (es) * 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
EP0619115A1 (en) * 1993-04-01 1994-10-12 Amgen Inc. Container comprising a metered dose valve and microparticles of a drug for topical treatment of skin disorders
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
EP0774956A1 (en) 1994-08-09 1997-05-28 Schering Corporation PROCESS FOR PREPARING BECLOMETHASONE DIPROPIONATE FREON$m(3) CLATHRATE
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5700487A (en) * 1996-03-04 1997-12-23 The Ohio State University Treatment of pulmonary inflammation
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
EP0935415B1 (en) * 1996-05-01 2006-11-22 Imarx Pharmaceutical Corp. In vitro methods for delivering nucleic acids into a cell
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US6380222B2 (en) * 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
SE9603725D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New teatment
AU741076B2 (en) 1996-12-12 2001-11-22 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
HU227183B1 (en) 1997-04-28 2010-09-28 Encysive Pharmaceuticals Inc Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
AU2868099A (en) 1998-02-13 1999-08-30 Selective Genetics, Inc. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
EP1925320A3 (en) 1998-03-27 2008-09-03 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
AU5116099A (en) * 1998-07-21 2000-02-14 Sui Xiong Cai Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
CA2395684C (en) 1999-12-31 2012-01-03 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US7109315B2 (en) 2000-03-15 2006-09-19 Bruce J. Bryan Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6485707B2 (en) 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6596262B2 (en) 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
AUPR868201A0 (en) * 2001-11-05 2001-11-29 Thorlock International Limited Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
EP1465882B1 (en) * 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Hetrocyclic modulators of nuclear receptors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US20030199594A1 (en) * 2002-04-23 2003-10-23 Rasik Shah Helium propellant composition for use with aerosols
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
EP1517684B1 (en) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
AU2003249742A1 (en) 2002-07-02 2004-01-23 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
CN1738797A (zh) 2002-11-19 2006-02-22 阿基里昂药品公司 取代的芳基硫脲和相关的化合物,病毒复制的抑制剂
EP1575648A4 (en) * 2002-12-18 2007-07-04 Glaxo Group Ltd DRUG DELIVERY SYSTEM WITH A VENTILATED MOUTHPIECE
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JP4847868B2 (ja) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
PT1635824E (pt) * 2003-06-03 2009-11-24 Novartis Ag Inibidores de p-38 à base de heterociclos de 5 membros
EP1911754B1 (en) 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2005113523A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2006009876A2 (en) * 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
EP1786421A2 (en) * 2004-07-09 2007-05-23 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
EP1841749A1 (en) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
AU2005287137B2 (en) 2004-09-17 2012-03-22 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods of inhibiting a-synuclein toxicity
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
EP1877434A2 (en) * 2005-05-04 2008-01-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
BRPI0609191B8 (pt) * 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SI1940457T1 (sl) * 2005-10-21 2013-04-30 Catalyst Biosciences, Inc. Modificirane proteaze, ki inhibirajo komplementno aktivacijo
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
CN101443314B (zh) * 2006-03-13 2014-04-09 杏林制药株式会社 作为gsk-3抑制剂的氨基喹诺酮类
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
EA200870385A1 (ru) * 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
MX2009002151A (es) 2006-08-28 2009-07-03 Kirin Pharma Kk Anticuerpos monoclonales humanos especificos para light humano antagonistas.
PT2066662E (pt) 2006-09-21 2013-02-13 Kyorin Seiyaku Kk Inibidores de serina-hidrolase
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2145878A3 (en) 2006-10-09 2010-02-24 Takeda Pharmaceutical Company Limited Aurora Kinase inhibitors
EP2089359A2 (en) 2006-10-31 2009-08-19 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2009070164A1 (en) 2007-11-28 2009-06-04 University Of Central Florida Vigor enhancement via administration of pyrimidine derivatives
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2125739A1 (en) * 2006-12-22 2009-12-02 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
PL2144604T3 (pl) * 2007-02-28 2012-02-29 Conatus Pharmaceuticals Inc Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
CN101855228B (zh) * 2007-09-11 2012-10-24 杏林制药株式会社 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
EP2203459B1 (en) 2007-09-12 2016-03-16 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as gsk-3 inhibitors
GEP20125704B (en) 2007-09-25 2012-12-10 Takeda Pharmaceuticals Co Plk kinase inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
JP2011504485A (ja) 2007-11-21 2011-02-10 ファーマクシス リミテッド Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
KR20130116386A (ko) 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20110178070A1 (en) 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
SG172064A1 (en) 2008-12-09 2011-07-28 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
BRPI1007378A2 (pt) 2009-01-06 2020-08-18 Curemark Llc composições e métodos para o tratamento ou prevenção de infecções por staphylococcus aureus e para a erradicação ou redução de staphylococcus aureus sobre superfícies.
EP2947100B1 (en) 2009-01-06 2019-05-08 Galenagen, LLC Oral compositions for the treatment or the prevention of infections by E. Coli
JP5649589B2 (ja) * 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用
EP2406266B1 (en) * 2009-03-11 2013-12-25 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
JP5730281B2 (ja) 2009-03-27 2015-06-10 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US8541417B2 (en) 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EP2499282B1 (en) 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
US8710092B2 (en) * 2009-12-23 2014-04-29 Map Pharmaceuticals, Inc. Substituted indolo 4,3 FG quinolines useful for treating migraine
JP5540454B2 (ja) * 2009-12-30 2014-07-02 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド ジペプチジルペプチダーゼ阻害剤
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
WO2011163636A2 (en) 2010-06-24 2011-12-29 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
HUE050873T2 (hu) 2011-04-21 2021-01-28 Curemark Llc Vegyületek neuropszichiátriai rendellenességek kezelésére
BR112013033339A2 (pt) 2011-06-23 2016-08-16 Map Pharmaceuticals Inc análogos de fluorergolina
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2013095707A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
RS59703B1 (sr) 2011-12-30 2020-01-31 Halozyme Inc Varijante ph20 polipeptida, njihove formulacije i upotrebe
EP2822936B1 (en) 2012-03-07 2021-09-08 The McLean Hospital Corporation Aminoquinoline derivatives and uses thereof
DK2833905T3 (en) 2012-04-04 2018-07-30 Halozyme Inc Combination therapy with hyaluronidase and a tumor-targeted taxane
AU2013255103B2 (en) 2012-05-02 2016-09-29 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2861562B1 (en) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
EP2934143A4 (en) 2012-12-21 2016-06-15 Map Pharmaceuticals Inc NOVEL DERIVATIVES OF METHYSERGIDE
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
JP6490597B2 (ja) 2013-02-22 2019-03-27 ユニヴァーシティー オブ サザン カリフォルニア 眼の疾患および障害を治療するための方法
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
RU2688163C2 (ru) 2013-03-15 2019-05-20 Юниверсити Оф Саузерн Калифорния Способы, соединения и композиции для лечения связанных с ангиотензином заболеваний
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3444011A1 (en) 2014-05-12 2019-02-20 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with emricasan
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
JP6625627B2 (ja) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法
US20170354639A1 (en) 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
AU2015338946B2 (en) 2014-10-31 2020-06-11 The General Hospital Corporation Potent gamma-secretase modulators
ES2834739T3 (es) 2014-12-11 2021-06-18 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
EP3237450B1 (en) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
CN107428745A (zh) 2015-01-20 2017-12-01 Xoc制药股份有限公司 麦角灵化合物及其用途
EP3247357A4 (en) 2015-01-20 2018-07-11 Xoc Pharmaceuticals, Inc Isoergoline compounds and uses thereof
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
EP3289104B1 (en) 2015-04-29 2020-11-04 New York University Method for treating high-grade gliomas
CN113603784A (zh) 2015-05-29 2021-11-05 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
DK3277842T5 (da) 2015-08-17 2020-08-31 Kura Oncology Inc Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
MX2018002315A (es) 2015-09-01 2018-04-11 Agenus Inc Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
SG11201805480TA (en) 2015-12-31 2018-07-30 Conatus Pharmaceuticals Inc Methods of using caspase inhibitors in treatment of liver disease
JP6880037B2 (ja) 2016-01-08 2021-06-02 セルジーン コーポレイション がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
EP3808346B1 (en) 2016-01-08 2023-07-19 Celgene Corporation Antiproliferative compounds for use in the treatment of leukemia
US10189808B2 (en) 2016-01-08 2019-01-29 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
EP3426352A4 (en) 2016-03-08 2019-11-13 Los Gatos Pharmaceuticals, Inc. CAMPTOTHECIN DERIVATIVES AND USES THEREOF
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US20190160052A1 (en) 2016-05-13 2019-05-30 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
JP7267012B2 (ja) 2016-05-27 2023-05-01 アジェナス インコーポレイテッド 抗ｔｉｍ－３抗体及びその使用方法
JP2019525772A (ja) 2016-07-08 2019-09-12 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
KR20190082247A (ko) 2016-11-03 2019-07-09 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
KR102003179B1 (ko) 2017-02-21 2019-07-23 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
SI3618863T1 (sl) 2017-05-01 2023-12-29 Agenus Inc. Protitelesa proti tigitu in načini uporabe njih
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
BR112019025420A2 (pt) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. Compostos policíclicos e usos destes
SG10202110500TA (en) 2017-06-22 2021-11-29 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load
US11560425B2 (en) 2017-06-27 2023-01-24 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating cancers
JP7034499B2 (ja) 2017-06-27 2022-03-14 ニューラクル サイエンス カンパニー リミテッド 線維症の治療のための抗ｆａｍ１９ａ５抗体の用途
EP3645563A4 (en) 2017-06-27 2021-03-17 Neuracle Science Co., Ltd ANTI-FAM19A5 ANTIBODIES AND THEIR USES
KR102472683B1 (ko) 2017-06-27 2022-12-01 주식회사 뉴라클사이언스 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP7325400B2 (ja) 2017-08-07 2023-08-14 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP4265257A1 (en) 2017-09-01 2023-10-25 East Carolina University Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
US20190216751A1 (en) 2017-11-15 2019-07-18 California State University Northridge Compositions and Methods for the Treatment and Prevention of Cancer
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CN112424223A (zh) 2018-04-24 2021-02-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
KR102661891B1 (ko) 2018-05-10 2024-05-23 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
KR20240067973A (ko) 2018-07-11 2024-05-17 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
MX2021000786A (es) 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3113575A1 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
CN113286591A (zh) 2018-11-01 2021-08-20 库拉肿瘤学公司 用法尼基转移酶抑制剂治疗癌症的方法
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
JP2022514654A (ja) 2018-12-21 2022-02-14 クラ オンコロジー， インコーポレイテッド 扁平上皮癌のための治療法
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
MX2021007843A (es) 2018-12-28 2021-08-11 Vertex Pharma Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso.
WO2020163554A1 (en) 2019-02-06 2020-08-13 Dice Alpha, Inc. Il-17a modulators and uses thereof
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3176660A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US11597703B2 (en) 2019-03-07 2023-03-07 Histogen, Inc. Caspase inhibitors and methods of use thereof
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
KR20210144778A (ko) 2019-03-29 2021-11-30 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CN114222803A (zh) 2019-05-20 2022-03-22 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
BR112022004802A2 (pt) 2019-09-16 2022-08-23 Dice Alpha Inc Moduladores de il-17a e usos dos mesmos
WO2021097144A2 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
EP4232070A1 (en) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Methods of inducing stem cell mobilization
EP4236989A1 (en) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Use of interleukin-7 for the treatment of coronavirus
EP4240408A1 (en) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
EP4284377A1 (en) 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
US12017997B2 (en) 2021-10-22 2024-06-25 Prosetta Biosciences, Inc. Host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US20230331693A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the novel compounds
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
US20240209100A1 (en) 2022-10-21 2024-06-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849460A (en) * 1953-11-17 1958-08-26 Olin Mathieson Purification of steroids
BE556587A (es) * 1957-01-31 1957-04-11
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
NL6810103A (es) * 1967-07-31 1969-02-04
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US4119548A (en) * 1977-10-28 1978-10-10 Mobil Oil Corporation Reaction product of nickel thiobis(alkylphenolate) and thiobis(alkylphenol) and organic compositions containing the same

Also Published As

Publication number Publication date
JPS531814B2 (es) 1978-01-23
JPS4919014A (es) 1974-02-20
IE37541B1 (en) 1977-08-17
AT348115B (de) 1979-01-25
US4364923A (en) 1982-12-21
FI53067C (es) 1978-02-10
LU67462A1 (es) 1973-07-05
PH13620A (en) 1980-08-07
NO140303C (no) 1979-08-08
IE37541L (en) 1973-10-20
ATA352973A (de) 1978-06-15
SE399642B (sv) 1978-02-27
US4414209A (en) 1983-11-08
NL157797B (nl) 1978-09-15
YU108673A (en) 1982-06-30
YU39602B (en) 1985-03-20
ES413911A1 (es) 1976-06-16
AR196524A1 (es) 1974-02-06
IL42038A0 (en) 1973-06-29
FI53067B (es) 1977-10-31
AU5466073A (en) 1974-10-24
AU471577B2 (en) 1976-04-29
DK134923B (da) 1977-02-14
DE2320111C2 (de) 1986-12-04
ZA732713B (en) 1974-11-27
FR2182981B1 (es) 1976-12-31
GB1429184A (en) 1976-03-24
NO140303B (no) 1979-04-30
HU171209B (hu) 1977-12-28
IL42038A (en) 1976-11-30
DK134923C (es) 1977-07-04
FR2182981A1 (es) 1973-12-14
NL7305438A (es) 1973-10-23
DE2320111A1 (de) 1973-10-31
BE798458A (fr) 1973-10-19

Similar Documents

Publication Publication Date Title
CA994753A (en) Solvates of antiinflammatory steroids and their use in aerosol formulations
AU5614973A (en) Combustible compositions and method of use
IL41160A0 (en) Novel steroids of the pregnane series and their preparation
AU5957873A (en) Foamed materials and their preparation
AU469449B2 (en) Improvement' in and relating tothe manufacture of concrete products
AU503505B2 (en) 13-ethynyl and 13-halovinyl steroids
CA907514A (en) Desensitizing compositions and the method of making and using the same
AU473526B2 (en) Bis-basic ethers of 9-substituted phenanthrene ano related 10-oxa and 10-aza derivatives
AU472635B2 (en) 2, 7-bis-basic esters and ethers of 9-benzylidenefluorene
AU461002B2 (en) Improvements in and relating tothe manufacture of hose
CA1011011A (en) Anti-fogging material and method of making same
CA911999A (en) Tetrahalo cyclopentanopolyhydro phenanthrene derivatives and compositions thereof
CA975753A (en) Steroidal pyrazole and process
CA898875A (en) Laser material and method of use thereof
CA914067A (en) Phenylpropiophenones and method of use
CA913068A (en) Steroid estrogen sulfates and methods of preparing the same
CA899530A (en) Foam compositions and method of preparation thereof
CA890942A (en) Ester-containing polyols and use in preparation of urethane compositions
CA901004A (en) Ester-containing polyols and use in preparation of urethane compositions
CA908325A (en) Foamed materials and their preparation
AU479821B2 (en) Silyesters and their use for modification of rubbers
CA975206A (en) Graphic aid and methods related thereto
CA1013491A (en) Preparation and formulation of polyurethane foams
AU484369B2 (en) Improvements in or relating to methods of dispensing material and/or dispensing means
CA892079A (en) Foam materials and their manufacture